CTX:CC News and Press, Crescita Therapeutics Inc. From 06/01/23

Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe Canada NewsWire VIENNA , June 1, 2023 /CNW/ -- Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliagl...

Strong Performance in Commercial Skincare Cash Balance of $10.3M Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driven Canadian commercial dermatology company,...

Record Annual Revenue of $23.5M, Up 40% Over F2021 F2022 Adjusted EBITDA 1 of $2.2M, Up 138% Over F2021 Crescita Therapeutics Inc. ( TSX: CTX and OTC US: CRRTF ) (“ Crescita ” or the “ Company ”), a growth-oriented, innovation-driv...

Sales Doubled with New Manufacturing Revenue Record of $4.3M Adjusted EBITDA 1 of $0.5M, up $1.0M Year-over-Year Cash Balance of $10.7M Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a gr...

Over 120% sales growth with Record Manufacturing Revenue of $3.9M Adjusted EBITDA 1 of $0.6M, up $0.9M Year-over-Year Repayment of $1.0 M of Convertible Debentures Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the &#...

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its 2022 Annual General and Special Meeting of Shareho...

Record Manufacturing Segment Revenue of $3.4M Positive Adjusted EBITDA 1 Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology compan...

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”) today announced that its CEO, Serge Verreault, will be presenting at the 2022 Bloom Burton & Co. Healthcare Investor Conference, to be held on May 2 and 3, 2022, featuring...

– Record Q4, and F2021 Manufacturing Segment Revenue of $5.3M, a 3-fold Increase vs. F2020 – Expansion of Pliaglis ® Licenses to 32 New Countries – Strong Liquidity Position of $11.3M – Q4-F2021 Adjusted EBITDA 1 of $1.6M Crescita T...